

20 June 2025

Treatment of Haematology in Secondary Care

Section 1

Q1. How many patients were treated in total, regardless of diagnosis, with the following medicines in the three months between the start of January 2025 and end of March 2025, or latest three month period available?

Name of medicine	Number patients treated
1.1 Fedratinib (Inrebic)	<5
1.2 Momelotinib (Omjjara)	<5
1.3 Ruxolitinib (Jakavi)	37
1.4 Hydroxycarbamide	84 (dispensed to patient but may be more treated as inpatient from ward stock)

Q2. How many patients were treated for the following myeloproliferative diseases in the three months between the start of January 2025 and end of March 2025, or latest three month period available?

Diagnosis with ICD10 codes	Number patients treated
2.1 Polycythaemia vera ICD10 codes = D45, D45.0, D45.0, D45X OR morphology code = 9950/3	
2.2 Myelofibrosis ICD10 codes = C944, C94.4 or D474, D47.4; OR morphology codes = 9931/3 or 9961/3	
2.3 Essential thrombocythemia ICD10 code = D473, D47.3 OR morphology code = 9962/3	
2.4 Myeloproliferative Disease, Chronic ICD10 code = D471, D47.1	

20 June 2025

Q3. How many patients with Myelofibrosis (ICD10 codes = C944 or D474; OR morphology codes = 9931/3 or 9961/3) were treated with the following medicines in the three months between the start of January 2025 and end of March 2025, or latest three month period available?

Name of medicine	Number patients treated
3.1 Ruxolitinib (Jakavi)	Allogeneic x <5 Autologous x 13 MUDs referred away x 5
3.2 Hydroxycarbamide	Not haematology

Section 2

Q4. How many patients were treated in total, regardless of diagnosis, with the following medicines in the three months between the start of January 2025 and end of March 2025, or latest three month period available?

Name of medicine	Number patients treated
4.1 Acalabrutinib (Calquence)	25
4.2 Ibrutinib (Imbruvica)	24
4.3 Pirtobrutinib (Jaypirca)	<5
4.4 Venetoclax (Venclyxto)	26
4.5 Zanubrutinib (Brukinsa)	20
4.6 Rituximab	56
4.7 Obinutuzumab (Gazyvaro)	13

Q5. How many patients with Chronic Lymphocytic Leukaemia OR Small B-Cell Lymphoma – ICD10 codes = C911, C91.1 OR C830, C83.0 - were treated with the following medicines in the three months between the start of January 2025 and end of March 2025, or latest three month period available?

20 June 2025

Name of medicine	Number patients treated
5.1 Acalabrutinib (Calquence)	
5.2 Ibrutinib (Imbruvica)	
5.3 Pirtobrutinib (Jaypirca)	
5.4 Venetoclax (Venclyxto)	
5.5 Zanubrutinib (Brukinsa)	
5.6 Obinutuzumab (Gazyvaro)	
5.7 Rituximab	
5.8 Bendamustine	
5.9 Chlorambucil	
5.10 Fludarabine	
5.11 Cyclophosphamide	

Q6. How many patients with Chronic Lymphocytic Leukaemia OR Small B-Cell Lymphoma were treated with the following medicines as monotherapy, or in combination, in the three months between the start of January 2025 and end of March 2025, or latest three month period available?

Name of monotherapy or combination	Number patients treated
6.1 Ibrutinib + venetoclax	
6.2 Obinutuzumab + venetoclax	
6.3 Zanubrutinib monotherapy / maintenance	
6.4 Ibrutinib monotherapy / maintenance	
6.5 Venetoclax monotherapy	
6.6 Venetoclax + rituximab	
6.7 Rituximab monotherapy	

20 June 2025

Q7. How many patients with Mantle Cell Lymphoma (ICD-10 code = C83.1) were treated with the following medicines, in the three months between the start of January 2025 and end of March 2025, or latest three month period available?

Name of monotherapy or combination	Number patients treated
7.1 Acalabrutinib	
7.2 Ibrutinib	
7.3 Zanubrutinib	

Section 3

Q8. How many transplantations took place in the three months between the start of January 2025 and end of March 2025, or latest three month period available?

Transplants	Number transplantations
8.1 Haematopoietic Stem Cell Transplants (HSCT)	
8.2 Solid organ transplants	

Q9. How many people receiving transplantation were also treated with these products in the three months between the start of January 2025 and end of March 2025, or latest three month period available?

Name of product	Haematopoietic stem cell transplant	Solid organ transplant
9.1 Letermovir (Prevymis)		
9.2 Valganciclovir (Valcyte, valganciclovir)		
9.3 Maribavir (Livtency)		
9.4 Ganciclovir (Cymevene)		
9.5 Cidofovir		
9.6 Foscarnet		

20 June 2025

Q10. Specifically how many people were treated with the following products for Cytomegalovirus post Haematopoietic Stem Cell Transplant in the three months between the start of January 2025 and end of March 2025, or latest three month period available?

Transplants	Number people
10.1 Letermovir (Prevymis)	
10.2 Valganciclovir (Valcyte, valganciclovir)	
10.3 Maribavir (Livtency)	
10.4 Ganciclovir (Cymevene)	
10.5 Cidofovir	
10.6 Foscarnet	

Q11. How many patients were treated with the following products and in these clinics / departments in the three months between the start of January 2025 and end of March 2025, or latest three month period available?

Name of product	In Total	Haematology	Paediatric haematology	Blood and marrow transplant service
11.1 Letermovir (Prevymis)	10 (dispensed to patient but may be more treated as inpatient from ward stock)			
11.2 Valganciclovir (Valcyte, valganciclovir)	13 (dispensed to patient but may be more treated as inpatient from ward stock)			
11.3 Maribavir (Livtency)	2 (dispensed			

20 June 2025

	to patient but may be more treated as inpatient from ward stock)			
11.4 Ganciclovir (Cymevene)	0			
11.5 Cidofovir	0			
11.6 Foscarnet	0			

NB: This information has been extracted from our recording system, encompass. Where blanks occur, we have been unable to extract the necessary information from our recording system. If a question is asking about a drug linked to a specific diagnosis, we cannot provide that information because electronic prescribing is not in place for the haematology service.